Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus short-course platinum doublet chemotherapy in elderly unresectable locally advanced or metastatic NSCLC
ChiCTR2500107013Phase 3Not yet recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of cadonilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Objective response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500107013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107013.